Acurx Pharmaceuticals, Inc. (ACXP)

Acurx Pharmaceuticals' stock has experienced significant volatility, declining by 67.67% over the last six months and 79.07% from January 13, 2025, to January 9, 2026. Key events include a 1-for-20 reverse stock split on July 31, 2025, regaining Nasdaq compliance on September 3, 2025, reporting Q3 2025 financial results on November 12, 2025, and announcing a Bitcoin conversion plan on November 20, 2024.

Information regarding demand seasonality for Acurx Pharmaceuticals, Inc. products and services is not available in the provided search results.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing new antibiotics to combat infections caused by priority pathogens. The company develops antibiotic candidates with a Gram-positive selective spectrum. Its lead product candidate, Ibezapolstat, is in Phase 2b clinical trials for CDI and is considered Phase 3 ready. ACX-375C is a potential treatment targeting Gram-positive bacteria, and the company is also exploring treatments for inhaled anthrax.

Acurx Pharmaceuticals is headquartered in Staten Island, New York, and primarily develops antibiotics for the United States. The company plans to begin international clinical trials for ibezapolstat, pending financing.

Acurx Pharmaceuticals announced the publication of its research in Nature Communications and presented new data at the IDWeek 2025 Scientific Conference. The Australian Patent Office granted Acurx a patent for DNA Polymerase IIIC Inhibitors, and the EMA issued a positive opinion on its Pediatric Investigation Plan for Ibezapolstat.

Acurx Pharmaceuticals has 17 institutional owners and shareholders holding a total of 55,793 shares, representing 11.53% institutional ownership. Insider ownership stands at 8.46%. Major institutional owners include Prospect Financial Services LLC, Susquehanna International Group, Llp, and Sabby Management, Llc.